High MICAL-L2 Expression and Its Role in the Prognosis of Colon Adenocarcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 May 3

PMID 35501725

Authors

Yixing Yang

Fengwen Ye

Tianxiang Xia

Qianwen Wang

Yujie Zhang

Jun Du

Affiliations

Soon will be listed here.

Abstract

Background: MICAL-like protein 2 (MICAL-L2), a member of the molecules interacting with CasL (MICAL) family of proteins, is strongly associated with the malignancy of multiple types of cancer. However, the role of MICAL-L2 in colon adenocarcinoma (COAD) has not been well characterized.

Methods: In this study, we analyzed the role of MICAL-L2 in COAD using datasets available from public databases. The mRNA and protein expression of MICAL-L2 was investigated using TCGA, UALCAN, and independent immunohistochemical assays. Overall survival (OS) and disease-specific survival (DSS) of COAD patients were assessed based on the MICAL-L2 expression level using the Kaplan-Meier method. Univariate and multivariate analysis was employed to determine whether MICAL-L2 could serve as an independent prognostic indicator of OS. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) were further utilized to explore the possible cellular mechanism underlying the role of MICAL-L2 in COAD. In addition, the correlation between MICAL-L2 expression and immune cell infiltration levels was investigated via single-sample gene set enrichment analysis (ssGSEA).

Results: Data from TCGA, HPA, and UALCAN datasets indicated that MICAL-L2 expression was significantly higher in COAD tissue than in adjacent normal tissues, and this was confirmed by immunohistochemical assays. Kaplan-Meier survival analysis revealed that patients with MICAL-L2 had shorter OS and DSS. Furthermore, multivariate Cox analysis indicated that MICAL-L2 was an independent risk factor for OS in COAD patients. ROC analysis confirmed the diagnostic value of MICAL-L2, and a prognostic nomogram involving age, M stage, and MICAL-L2 expression was constructed for OS. Functional enrichment analyses revealed that transport-related activity was closely associated with the role of MICAL-L2 in COAD. Regarding immune infiltration levels, MICAL-L2 was found to be positively associated with CD56 NK cells.

Conclusions: Our results suggested that MICAL-L2 is a promising biomarker for determining prognosis and correlated with immune infiltration levels in COAD.

Citing Articles

MICAL1 Mediates TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Activating Smad2/3.

Zhuang X, Wang C, Ge Z, Wu M, Chen M, Chen Z Cell Biochem Biophys. 2025; .

PMID: 39954154 DOI: 10.1007/s12013-025-01668-8.

Comprehensive Analysis of MICALL2 Reveals Its Potential Roles in EGFR Stabilization and Ovarian Cancer Cell Invasion.

Xia T, Ye F, Zhao W, Min P, Qi C, Wang Q Int J Mol Sci. 2024; 25(1).

PMID: 38203692 PMC: 10778810. DOI: 10.3390/ijms25010518.

MICALL2 as a substrate of ubiquitinase TRIM21 regulates tumorigenesis of colorectal cancer.

Wen P, Wang H, Li Y, Sui X, Hou Z, Guo X Cell Commun Signal. 2022; 20(1):170.

PMID: 36307841 PMC: 9615392. DOI: 10.1186/s12964-022-00984-3.

References

Zhang Q, Xia T, Qi C, Du J, Ye C . High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma. BMC Cancer. 2022; 22(1):77. PMC: 8764844. DOI: 10.1186/s12885-022-09180-5. View

Min P, Zhao S, Liu L, Zhang Y, Ma Y, Zhao X . MICAL-L2 potentiates Cdc42-dependent EGFR stability and promotes gastric cancer cell migration. J Cell Mol Med. 2019; 23(6):4475-4488. PMC: 6533512. DOI: 10.1111/jcmm.14353. View

Yoon J, Terman J . MICAL redox enzymes and actin remodeling: New links to classical tumorigenic and cancer pathways. Mol Cell Oncol. 2018; 5(1):e1384881. PMC: 5791864. DOI: 10.1080/23723556.2017.1384881. View

Qi C, Min P, Wang Q, Wang Y, Song Y, Zhang Y . MICAL2 Contributes to Gastric Cancer Cell Proliferation by Promoting YAP Dephosphorylation and Nuclear Translocation. Oxid Med Cell Longev. 2021; 2021:9955717. PMC: 8510804. DOI: 10.1155/2021/9955717. View

Giridharan S, Caplan S . MICAL-family proteins: Complex regulators of the actin cytoskeleton. Antioxid Redox Signal. 2013; 20(13):2059-73. PMC: 3993057. DOI: 10.1089/ars.2013.5487. View

Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

Wang Y, Min P, Qi C, Zhao S, Yu M, Zhang Y . MICAL2 Facilitates Gastric Cancer Cell Migration via MRTF-A-Mediated CDC42 Activation. Front Mol Biosci. 2021; 8:568868. PMC: 8024553. DOI: 10.3389/fmolb.2021.568868. View

Gu H, Li Y, Cui X, Cao H, Hou Z, Ti Y . MICAL1 inhibits colorectal cancer cell migration and proliferation by regulating the EGR1/β-catenin signaling pathway. Biochem Pharmacol. 2021; 195:114870. DOI: 10.1016/j.bcp.2021.114870. View

Nakatsuji H, Nishimura N, Yamamura R, Kanayama H, Sasaki T . Involvement of actinin-4 in the recruitment of JRAB/MICAL-L2 to cell-cell junctions and the formation of functional tight junctions. Mol Cell Biol. 2008; 28(10):3324-35. PMC: 2423145. DOI: 10.1128/MCB.00144-08. View

10.

Min P, Zhang L, Wang Y, Qi C, Song Y, Bibi M . MICAL-L2 Is Essential for c-Myc Deubiquitination and Stability in Non-small Cell Lung Cancer Cells. Front Cell Dev Biol. 2021; 8:575903. PMC: 7841116. DOI: 10.3389/fcell.2020.575903. View

11.

C Akinkuotu A, Maduekwe U, Hayes-Jordan A . Surgical outcomes and survival rates of colon cancer in children and young adults. Am J Surg. 2021; 221(4):718-724. DOI: 10.1016/j.amjsurg.2021.02.010. View

12.

Rubin D, Shaker A, Levin M . Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol. 2012; 3:107. PMC: 3347037. DOI: 10.3389/fimmu.2012.00107. View

13.

Sakane A, Yoshizawa S, Yokota H, Sasaki T . Dancing Styles of Collective Cell Migration: Image-Based Computational Analysis of JRAB/MICAL-L2. Front Cell Dev Biol. 2018; 6:4. PMC: 5807911. DOI: 10.3389/fcell.2018.00004. View

14.

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

15.

McGarry D, Armstrong G, Castino G, Mason S, Clark W, Shaw R . MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours. Cancer Lett. 2021; 519:226-236. DOI: 10.1016/j.canlet.2021.07.039. View

16.

Sun Y, Jaldin-Fincati J, Liu Z, Bilan P, Klip A . A complex of Rab13 with MICAL-L2 and α-actinin-4 is essential for insulin-dependent GLUT4 exocytosis. Mol Biol Cell. 2015; 27(1):75-89. PMC: 4694764. DOI: 10.1091/mbc.E15-05-0319. View

17.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

18.

Deng W, Gu L, Li X, Zheng J, Zhang Y, Duan B . CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells. J Transl Med. 2016; 14:32. PMC: 5439121. DOI: 10.1186/s12967-016-0787-y. View

19.

Wagner J, Rosario M, Romee R, Berrien-Elliott M, Schneider S, Leong J . CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017; 127(11):4042-4058. PMC: 5663359. DOI: 10.1172/JCI90387. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View